Angiogenesis therapy with human tissue kallikrein for the treatment of ischemic diseases.
Angiogenesis is essential for the repair of wounds and tissues damaged by ischemia. The regenerative process is tightly regulated by master angiogenic factors, cytokines and the downstream mediator NO. In addition, modulators of vascular growth, such as COX-2-generated prostanoids, contribute to the process by stabilizing the hypoxia-inducible factor and stimulating the expression of VEGF. Recently, we discovered that human tissue kallikrein, a member of the serine proteinase superfamily, possesses potent angiogenic effects. It has been categorized as a pleiotropic angiogenic agent acting via enzymatic cleavage of kininogen and subsequent release of kinin peptides. Kinins bind G-protein coupled receptors, subtype B1 and B2, and exert proliferative effects on endothelial cells via an IP3K-Akt-NO mediated mechanism independent of VEGF. In addition, kinins stimulate the release of angiogenic prostacyclin. Gene transfer of human tissue kallikrein rescues ischemic tissues in otherwise normal mice, as well as in hypertensive or diabetic animals. In addition, prophylactic gene delivery of tissue kallikrein to diabetic skeletal muscles prevents the development of microangiopathy and stimulates collateralization, thus protecting from the consequences of supervening arterial occlusion.
Experimental medicine and gene therapy section, National Institute of Biostructures and Biosystems, Osilo and Porto Conte, Osilo (SS), Italy.
C
C
Emanueli
P
P
Madeddu
D000818:Animals; D003029:Coagulants / Q000494:pharmacology* / Q000627:therapeutic use*; D048909:Diabetes Complications; D004195:Disease Models, Animal; D018014:Gene Transfer Techniques; D006801:Humans; D006973:Hypertension / Q000150:complications; D007610:Kallikreins / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use*; D051379:Mice; D017202:Myocardial Ischemia / Q000628:therapy / Q000662:veterinary; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D020521:Stroke / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A
D003029:Coagulants; D042461:Vascular Endothelial Growth Factor A; D007610:Kallikreins